The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2021 | Update on fixed-duration cohort of CAPTIVATE trial for CLL/SLL
Paolo Ghia, MD, Università Vita-Salute San Raffaele, Milan, Italy, gives an update on the Phase II CAPTIVATE trial (NCT02910583), investigating ibrutinib plus venetoclax for patients with treatment-naïve chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). There were two patient cohorts; one in which the duration of treatment was guided by measurable residual disease (MRD) levels and the other in which there was a fixed duration of treatment. Dr Ghia discusses the results of the fixed-duration cohort who received 3 cycles of ibrutinib, followed by 12 cycles of ibrutinib plus venetoclax. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
